Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
193.59B
Market cap193.59B
Price-Earnings ratio
10.26
Price-Earnings ratio10.26
Dividend yield
2.81%
Dividend yield2.81%
Average volume
12.59M
Average volume12.59M
High today
$44.37
High today$44.37
Low today
$42.71
Low today$42.71
Open price
$44.05
Open price$44.05
Volume
10.86M
Volume10.86M
52 Week high
$81.44
52 Week high$81.44
52 Week low
$35.12
52 Week low$35.12

NVO News

Simply Wall St 2h
Novo Nordisk Wegovy Trial With Veru Adds Underappreciated Obesity Angle

Novo Nordisk (NYSE:NVO) has entered a clinical supply agreement with Veru Inc. to provide Wegovy for a pivotal Phase 2b obesity trial in older adults. The agre...

Novo Nordisk Wegovy Trial With Veru Adds Underappreciated Obesity Angle
TipRanks 2d
Veru announces clinical supply agreement with Novo Nordisk

In a regulatory filing, Veru (VERU) announced that on June 2, the company entered into a clinical supply agreement with Novo Nordisk A/S (NVO) in conjunction wi...

TipRanks 2d
Novo Nordisk Expands Obesity and Diabetes Pipeline With New Phase 1 Trial of NNC0497-0040

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings...

Analyst ratings

54%

of 37 ratings
Buy
37.8%
Hold
54.1%
Sell
8.1%

More NVO News

The Motley Fool 2d
Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success

The pharmaceutical industry is highly technical and incredibly competitive. That is on clear display right now in the GLP-1 weight-loss space. These are newly i...

Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success
Bloomberg 2d
Denmark to Study Whether Wegovy Can Get More People Working

The new government in Novo Nordisk A/S ’s home country of Denmark wants to test whether weight-loss drugs can help get more people into work, adding a new econo...

Denmark to Study Whether Wegovy Can Get More People Working
TipRanks 2d
Major Insider Makes Bold Move in Prothena Stock

New insider activity at Prothena ( (PRTA) ) has taken place on June 3, 2026. Claim 55% Off TipRanks Unlock trusted, data-backed investing tools with TipRanks Pr...

Nasdaq 3d
Here's What I Think Is Really Going on With Novo Nordisk Stock

Key Points Novo Nordisk lost momentum in the GLP-1 market. The company's deep pipeline could allow it to bounce back. 10 stocks we like better than Novo Nord...

Here's What I Think Is Really Going on With Novo Nordisk Stock
Reuters 3d
Novo Nordisk launches Wegovy in UAE - Reuters

...

Novo Nordisk launches Wegovy in UAE - Reuters
The Wall Street Journal 3d
Novo Nordisk Launches Wegovy Weight-Loss Pill in UAE

The Emirates Drug Establishment said this week that it had approved Novo Nordisk's once-daily tablet. Novo Nordisk Novo Nordisk NOVO.B -2.54 %decrease; red dow...

Novo Nordisk Launches Wegovy Weight-Loss Pill in UAE
Nasdaq 4d
Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down

Key Points VK2735 is being developed in both subcutaneous and oral forms, and upcoming Phase 1 maintenance trial results are a major catalyst. VK2735 may offe...

Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.